 Shares of Intellia Therapeutics Inc. NTLA, 7.36 gained 6.5 in premarket trading on Friday after the company and Regeneron Pharmaceuticals Inc. REGN, 1.18 announced positive data from an ongoing Phase 1 clinical trial evaluating their investigational Crispr therapy as a treatment for transthyretin amyloidosis with cardiomyopathy, which can cause heart failure. The data demonstrated a reduction in serum transthyretin in 12 patients for up to six months. 